Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease

被引：2
|
作者：
Hanrahan, John P.
de Boer, Ian
Bakris, George
Wilson, Phebe
Wakefield, James D.
Seferovic, Jelena P.
Chickering, Jennifer
Cressman, Michael
Currie, Mark
Milne, George T.
Profy, Albert T.
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1073-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1073-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease A Randomized Placebo-Controlled Clinical Trial
    Hanrahan, John P.
    de Boer, Ian H.
    Bakris, George L.
    Wilson, Phebe J.
    Wakefield, James D.
    Seferovic, Jelena P.
    Chickering, Jennifer G.
    Chien, Yueh-tyng
    Carlson, Kenneth
    Cressman, Michael D.
    Currie, Mark G.
    Milne, G. Todd
    Profy, Albert T.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (01): : 59 - 69
  • [2] Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Heart Failure with Preserved Ejection Fraction (Capacity HFpEF): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
    Udelson, James E.
    Lewis, Gregory D.
    Shah, Sanjiv J.
    Zile, Michael R.
    Redfield, Margaret M.
    Burnett, John
    Parker, John D.
    Seferovic, Jelena
    Wilson, Phebe J.
    Mittleman, Robert S.
    Profy, Albert T.
    Konstam, Marvin A.
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S8 - S8
  • [3] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator The VICTORIA Trial
    Armstrong, Paul W.
    Roessig, Lothar
    Patel, Mahesh J.
    Anstrom, Kevin J.
    Butler, Javed
    Voors, Adriaan A.
    Lam, Carolyn S. P.
    Ponikowski, Piotr
    Temple, Tracy
    Pieske, Burkert
    Ezekowitz, Justin
    Hernandez, Adrian F.
    Koglin, Joerg
    O'Connor, Christopher M.
    JACC-HEART FAILURE, 2018, 6 (02) : 96 - 104
  • [4] An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
    John P. Hanrahan
    Jelena P. Seferovic
    James D. Wakefield
    Phebe J. Wilson
    Jennifer G. Chickering
    Joon Jung
    Kenneth E. Carlson
    Daniel P. Zimmer
    Andrew L. Frelinger
    Alan D. Michelson
    Linda Morrow
    Michael Hall
    Mark G. Currie
    G. Todd Milne
    Albert T. Profy
    Diabetologia, 2020, 63 : 733 - 743
  • [5] An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
    Hanrahan, John P.
    Seferovic, Jelena P.
    Wakefield, James D.
    Wilson, Phebe J.
    Chickering, Jennifer G.
    Jung, Joon
    Carlson, Kenneth E.
    Zimmer, Daniel P.
    Frelinger, Andrew L., III
    Michelson, Alan D.
    Morrow, Linda
    Hall, Michael
    Currie, Mark G.
    Milne, G. Todd
    Profy, Albert T.
    DIABETOLOGIA, 2020, 63 (04) : 733 - 743
  • [6] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF ENALAPRIL IN PATIENTS WITH CLINICAL DIABETIC NEPHROPATHY
    BAUER, JH
    REAMS, GP
    HEWETT, J
    KLACHKO, D
    MESSINA, C
    KNAUS, V
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (05) : 443 - 457
  • [7] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CHIGLITAZAR IN NASH PATIENTS
    You, Hong
    Sun, Yameng
    Wu, Cuisong
    Xin, Guijie
    Zhong, Bihui
    Wu, Xiaofeng
    Liu, Yali
    Shi, Junping
    Zhang, Qin
    Zhao, Yingren
    Gao, Yufeng
    Xin, Yongning
    Zhu, Yueyong
    Wu, Lixian
    Mao, Xiaorong
    Du, Jian
    Shang, Jia
    Sun, Weiwei
    Xu, Jie
    Yu, Zujiang
    Nan, Yuemin
    Sheng, Huiping
    Li, Yue
    Rao, Huiying
    Yu, Chaohui
    Wu, Xiaoning
    Tong, Xiaofei
    HEPATOLOGY, 2024, 80 : S1969 - S1970
  • [8] Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
    Butchart, Joseph
    Brook, Laura
    Hopkins, Vivienne
    Teeling, Jessica
    Puentener, Ursula
    Culliford, David
    Sharples, Richard
    Sharif, Saif
    McFarlane, Brady
    Raybould, Rachel
    Thomas, Rhodri
    Passmore, Peter
    Perry, V. Hugh
    Holmes, Clive
    NEUROLOGY, 2015, 84 (21) : 2161 - 2168
  • [9] ETANERCEPT IN ALZHEIMER DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 2 TRIAL
    Tufan, Ayse N.
    Tufan, Fatih
    NEUROLOGY, 2015, 85 (23) : 2083 - 2084
  • [10] Rationale and design for a multicenter, randomized, double-blind, placebo- controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)
    Udelson, James E.
    Lewis, Gregory D.
    Shah, Sanjiv J.
    Zile, Michael R.
    Redfield, Margaret M.
    Burnett, John, Jr.
    Mittleman, Robert S.
    Profy, Albert T.
    Seferovic, Jelena P.
    Reasner, David
    Konstam, Marvin A.
    AMERICAN HEART JOURNAL, 2020, 222 : 183 - 190
12345